The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.
The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term
Company Details
- Address
- Ιωαννίνων 455 00, Greece, Ioannina,greece 455 00,greece
- Industry
- Medical Device
- Website
- https://insilc.eu/
- HQ
- Ioannina, Greece
Insilc Eu Questions
Insilc Eu's website is https://insilc.eu/
Insilc Eu's LinkedIn profile is https://gr.linkedin.com/company/insilc-eu-h2020
Insilc Eu's industry is
Medical Device
Insilc Eu's top competitors are
Maruga Group,
Neuro-Hci Xr Research Team,
Amtc,
Bionics Solutions,
Mg Biotech,
Key Medical Solutions Ltd,
Madison Medical Greece,
Quantum Biometronics,
System Vision Biotechnology Sa,
Dermapharm Pcc.
Insilc Eu's categories are Medical Device
